What Merz Therapeutics does

Merz Therapeutics GmbH is the specialty therapeutics division of the privately held, family-owned Merz Group (founded 1908 in Germany). Headquartered in Frankfurt am Main, the company develops and commercializes prescription pharmaceutical products across three therapeutic areas: neurology, hepatology, and dermatology. Its core franchise is built on XEOMIN (incobotulinumtoxinA), a purified botulinum toxin type A with complexing proteins removed during manufacturing, approved in 79 countries for movement disorders (cervical dystonia, blepharospasm, spasticity, sialorrhea) and aesthetic indications. The portfolio is anchored by INBRIJA (levodopa inhalation powder), an FDA- and EMA-approved therapy for intermittent OFF episodes in Parkinson's disease, delivered via pulmonary absorption to bypass gastrointestinal variability. Legacy hepatology and dermatology brands—Hepa-Merz, Pantogar, and Contractubex—round out the portfolio.

The company operates a distribution-led business model, commercializing products through approximately 60 distribution partners across more than 80 countries in EMEA, LATAM, and APAC. Anchor partnerships include Teijin (Japan), Grünenthal (Latin America), and Kvvit (Greater China). As a privately held subsidiary of the Merz Group, Merz Therapeutics is funded by family ownership rather than external capital markets and reports no public revenue. Its workforce of approximately 940 employees spans 39 nationalities across offices in 12 countries, with U.S. research and regulatory operations based in North Carolina (Greensboro and Raleigh).

Recent strategic activity reflects an offensive expansion posture: new geographic entries via partnerships in Brazil and Greater China, indication-stacking for XEOMIN (Health Canada post-stroke spasticity approval, Japan MHLW cervical dystonia and blepharospasm approvals, EU pediatric spasticity filing), and expansion into the U.S. aesthetic neurotoxin market through the 2024-2025 FDA approval for simultaneous forehead, glabellar, and crow's feet treatment. Growth strategy is articulated explicitly through the company's 'commercial partnerships' and 'business and corporate development' functions, signaling continued reliance on licensing and partner-led commercialization rather than wholly owned sales infrastructure in most international markets.

Name

Merz Therapeutics

Legal name

Merz Therapeutics GmbH

Website

https://merztherapeutics.com

Company type

Private

Founded year

1908

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Merz Therapeutics is the specialty pharmaceutical division of family-owned Merz Group, developing and commercializing prescription therapies for movement disorders, Parkinson's disease, liver conditions, and dermatology across 80+ countries via a partner-led distribution model.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Botulinum toxin therapeutics
• Specialty neurology pharmaceuticals
• Movement disorder treatments
• Parkinson's disease therapies
• Hepatology dermatology products

Headquarters

HQ city

Frankfurt

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Merz Therapeutics generates revenue through the sale of prescription pharmaceutical products across neurology, hepatology, and dermatology therapeutic areas. Products include XEOMIN for movement disorders, INBRIJA for Parkinson's disease, and established brands in hepatology and dermatology.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Merz Therapeutics develops, manufactures and commercializes specialty pharmaceutical products centered on neurotoxin-based therapies and other prescription medicines. Its portfolio addresses neurology (movement disorders such as Parkinson's disease, spasticity, cervical dystonia, blepharospasm and sialorrhea), hepatology and dermatology, with XEOMIN (incobotulinumtoxinA) and INBRIJA (levodopa inhalation powder) as flagship neurology brands, alongside Hepa-Merz, Pantogar and Contractubex in its other therapeutic areas.

Product overview

Merz Therapeutics operates as a neurology-focused specialty pharmaceutical company offering a portfolio of therapeutic products across three main areas: Neurology, Hepatology, and Dermatology. The core neurology portfolio centers on XEOMIN® (incobotulinumtoxinA), a botulinum toxin product approved in 79 countries for treating movement disorders including cervical dystonia, blepharospasm, spasticity, and sialorrhea, as well as aesthetic indications. INBRIJA® (levodopa inhalation powder) addresses Parkinson's disease OFF episodes. The hepatology portfolio includes Hepa-Merz®, while dermatology offerings comprise Pantogar® for hair/nail conditions and Contractubex® for scar treatment. The company distributes through partnerships in over 80 countries worldwide, including significant distribution agreements with Teijin (Japan), Grünenthal (Latin America), and Kvvit (Greater China).

Differentiator

Problem solved

Functional benefit

Brands

• XEOMIN: Botulinum toxin product (incobotulinumtoxinA) for treating movement disorders including spasticity, cervical dystonia, blepharospasm, and aesthetic indications.
• INBRIJA
• Pantogar
• Hepa-Merz
• Contractubex

Products and services

• XEOMIN (incobotulinumtoxinA) Botulinum toxin type A product containing incobotulinumtoxinA as its sole active ingredient with complexing proteins removed during manufacturing. Indicated for movement disorders including cervical dystonia, blepharospasm, upper and lower limb spasticity, chronic sialorrhea, and aesthetic indications such as forehead, glabellar and crow's feet lines. Prescribed by neurologists, physiatrists and aesthetic practitioners.
• INBRIJA (levodopa inhalation powder) Inhaled levodopa medication for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult Parkinson's disease patients treated with a levodopa/dopa-decarboxylase inhibitor. Delivered directly to the lung via inhalation, with absorption unaffected by meals or gastrointestinal conditions. FDA approved in 2018 and EMA approved in 2019.
• Pantogar Pharmaceutical product for nail and hair conditions, used in dermatology indications. Commercialized in Brazil through partnership with Biolab Farmacêutica.
• Hepa-Merz Pharmaceutical product for liver conditions, used in hepatology indications for patients with chronic liver disease where liver function worsens over time. Commercialized in Brazil through partnership with Biolab Farmacêutica.
• Contractubex Pharmaceutical product for scar treatment, used in dermatology indications. Commercialized in Brazil through partnership with Biolab Farmacêutica.

Quantifiable outcome

• XEOMIN provides consistent and rapid motor improvement for OFF episodes with mean UPDRS-III score reductions of -14.3 (treatment <2 years) and -14.8 (treatment ≥2 years)
• +3 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered core.

• GrünenthalcoreChannel Partner/ Reseller/ Distributor · 1 July 2026Merz Therapeutics is strengthening its partnership with Grünenthal, extending collaboration into Brazil as of July 1, 2026. Grünenthal will take on commercialization responsibilities for XEOMIN from current local partner Biolab Farmacêutica. This builds on existing collaboration including partnerships in Colombia (June 2026) and ongoing partnerships in Mexico and Ecuador. Pantogar, Hepa-Merz and Contractubex commercialization remains with Biolab.
• Kvvit (Jiangxi Kvvit Pharmaceutical Co. Ltd.)coreChannel Partner/ Reseller/ Distributor · 26 May 2026Exclusive license and collaboration agreement for INBRIJA (levodopa inhalation powder) for mainland China, Hong Kong and Macao. Merz will supply INBRIJA and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercialization under a jointly agreed China Development Plan. Merz acts as Overseas Holder of Drug Registration Certificate while Kvvit serves as Domestic Responsible Person. INBRIJA is currently not approved in the licensed territory.
• Teijin Pharma LimitedcoreChannel Partner/ Reseller/ Distributor · 1 January 2017Teijin signed an exclusive license and co-development agreement for XEOMIN with Merz Therapeutics in 2017. Teijin launched exclusive sales of XEOMIN in Japan in December 2020 after obtaining manufacturing and marketing approval. In June 2026, Japan's MHLW approved additional indications for XEOMIN for cervical dystonia and blepharospasm - the fourth and fifth indications in Japan, alongside existing approvals for upper limb spasticity, lower limb spasticity and chronic sialorrhea.
• World Stroke Organization (WSO)coreStrategic or Co-development PartnerAccess to Health Initiative collaboration between Merz Therapeutics and World Stroke Organization, designed to address stroke care disparities in low- and middle-income countries. Piloted in Nigeria and Tanzania with plans for further expansion into Sub-Saharan Africa. Merz brings financial support, technical expertise and workforce engagement while WSO delivers on-the-ground network and stroke care knowledge.
• Patient Organizations NetworkcoreStrategic or Co-development PartnerMerz Therapeutics has established close partnerships with patient organizations including SAFE (Stroke Alliance for Europe), Dystonia Europe, EPDA (Parkinson's Europe), Parkinson's Foundation, Dystonia Medical Research Foundation, Michael J. Fox Foundation, Cerebral Palsy Alliance Research Foundation, and PMD Alliance. These partnerships help understand and address patient needs through clinical trial design engagement and dedicated research.
• Teijin (Japan Distribution)coreChannel Partner/ Reseller/ DistributorTeijin serves as Merz's distribution partner for XEOMIN in Japan, with the collaboration enabling expansion across over 90 countries. Growth initiatives target Asia and Latin America through distribution partnerships.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Allergan Aesthetics (AbbVie): Allergan Aesthetics, an AbbVie subsidiary, manufactures Botox, the market-leading botulinum toxin. Directly comparable to Merz Therapeutics via XEOMIN in both therapeutic neurology indications (spasticity, cervical dystonia, blepharospasm) and aesthetic indications (forehead lines, glabellar lines, crow's feet).
• Ipsen: Ipsen markets Dysport (abobotulinumtoxinA), a competing botulinum toxin product approved in therapeutic and aesthetic indications globally. Headquartered in France with overlapping geographic reach to Merz, Ipsen is a direct competitor in the botulinum toxin category and broader specialty neurology.
• Revance Therapeutics: Revance markets DaxibotulinumtoxinA (Daxxify), a next-generation botulinum toxin approved for both therapeutic (cervical dystonia) and aesthetic indications. Revance directly competes with Merz's XEOMIN in the same physician channels and indication categories.
• Supernus Pharmaceuticals: Supernus is a US specialty pharmaceutical company focused on CNS disorders including Parkinson's disease, epilepsy, and ADHD. Comparable to Merz Therapeutics as a CNS-focused specialty pharma targeting similar neurology prescribers, though without botulinum toxin overlap.
• US WorldMeds: US WorldMeds is a specialty pharmaceutical company with a neurology focus, including products in spasticity and movement disorders. Comparable to Merz Therapeutics as a smaller, specialty-neurology-focused competitor targeting similar prescribers and patient populations.

Emerging players

• Evolus: Evolus markets Jeuveau (prabotulinumtoxinA), a newer botulinum toxin focused primarily on aesthetics. While smaller and more aesthetics-focused than Merz, Evolus competes in the same physician-administered neurotoxin market as XEOMIN.

Broad incumbents

• Lundbeck: Lundbeck is a global specialty pharmaceutical company focused on neurology and psychiatry. While not a direct competitor in botulinum toxin, Lundbeck competes in Parkinson's disease and CNS therapeutics, overlapping with Merz's neurology franchise and target prescribers.
• Galderma: Galderma is a global dermatology-focused pharmaceutical company with aesthetic and therapeutic offerings. Comparable to Merz's dermatology franchise (Pantogar, Contractubex) and overlapping aesthetics market via XEOMIN's cosmetic indications.
• AbbVie: AbbVie, parent of Allergan Aesthetics, is a global biopharmaceutical company with substantial neurology and aesthetics portfolios. Comparable to Merz Therapeutics through Allergan's Botox franchise and broader CNS portfolio, including Parkinson's disease therapies that overlap with INBRIJA's target market.
• Bausch + Lomb (formerly Bausch Health): Bausch + Lomb is a specialty pharmaceutical and medical device company with neurology, dermatology, and aesthetics exposure. Comparable to Merz Therapeutics as a diversified specialty pharma with some overlapping therapeutic areas and physician channel relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInde.linkedin.com/company/merz-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merz Therapeutics